Telix Pharmaceuticals Limited

Directions Website

Telix Pharmaceuticals Limited Listed on the ASX and Nasdaq under the ticker TLX. You are encouraged to report negative side effects of prescription drugs to the FDA.

Telix is a global biopharmaceutical company focused on developing and commercializing radiopharmaceuticals to address significant unmet medical need in oncology and rare diseases. Telix is a clinical-stage biopharmaceutical company developing diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, and the United States. Telix is developing a portfolio of clinical-stage products that address significant unmet medical needs in oncology and rare diseases. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report adverse reactions to Telix by calling 1-844-455-8638 or emailing [email protected]. Please see full Illuccix Prescribing Information:https://illuccixhcp.com/wp-content/uploads/illuccix-prescribing-information.pdf

12/10/2026

In addition to consistently high image quality, 68Ga-PSMA-11 PET offers practical advantages.

In this second episode of Radiopharma Unpacked, Dr. Paul Yonover explains how a same-day workflow suited to high volume services has helped establish gallium-based PSMA-PET as a standard of care in prostate cancer imaging.

Watch the full episode here: https://bit.ly/47VCQ69

12/10/2026

Thank you to Krystyna and husband Ted for describing her courageous battle with brain cancer and what an approved imaging agent for glioma means for patients and their families.

We’re grateful to them and to our partners at IU Health for helping raise awareness.

Video credit: IU Health Social Media

09/10/2026

Rounding out our Nuclear Medicine & Molecular Imaging Week spotlight is Dr. Neha Vapiwala.

Her career sits at the intersection of radiation oncology and nuclear medicine, two specialties that increasingly depend on each other, and on people willing to build the bridge between them.

Thank you to Dr. Vapiwala, Dr. Esfahani, Dr. Corzo and to everyone advancing theranostics for the benefit of patients.

Inspired by their stories? Explore careers at Telix: https://telixpharma.com/careers/

Institutional investors and analysts are invited to join us in-person in Melbourne for Telix’s 2026 Capital Markets Day ...
08/10/2026

Institutional investors and analysts are invited to join us in-person in Melbourne for Telix’s 2026 Capital Markets Day on November 4.

Members of the Telix leadership team and key opinion leaders will share the latest scientific, clinical and strategic developments across our therapeutic and precision medicine pipeline.

The event will be webcast live and available via the Investor Relations section of the Telix website.

Learn more and register: https://telixpharma.com/news-views/telix-to-host-capital-markets-day-in-melbourne-on-november-4-2026/

08/10/2026

This Nuclear Medicine & Molecular Imaging Week, we’re spotlighting women shaping the future of nuclear medicine.

With nearly 16 years in the field, Dr. Shadi Esfahani has helped build a theranostics research program focused on bringing new radiopharmaceuticals to patients who need them most.

Watch her story below. Inspired? Explore opportunities at Telix: https://telixpharma.com/careers/

06/10/2026

This Nuclear Medicine & Molecular imaging Week, we're taking the opportunity to highlight a few of the women that are helping to move the field forward.​

Dr. Valentina Marulanda Corzo is a postdoctoral research associate, working at the leading edge of theranostics in prostate cancer and neuro-oncology.

Her outlook has carried her through every step:​ "Whenever I see a wall, I am not thinking I'm stopping
— I'm thinking I'm going to climb this wall.“​

Watch Dr. Corzo’s video below and, if you are inspired by her story, take a look at the latest career opportunities at Telix: https://telixpharma.com/careers/​

The first patients have been dosed with Pixclara® (floretyrosine F 18), Telix’s FDA-approved PET imaging drug for glioma...
06/10/2026

The first patients have been dosed with Pixclara® (floretyrosine F 18), Telix’s FDA-approved PET imaging drug for glioma (brain cancer), marking the start of U.S. commercial availability.

Thanks to the patients and their care teams, and to our partners at Indiana University Health, Indianapolis (IN) and University Hospitals, Cleveland Medical Center, Cleveland (OH) for supporting this milestone. We also thank PharmaLogic, our U.S. manufacturing and pharmacy distribution partner for supplying unit doses.

Pixclara is the only FDA-approved radiopharmaceutical imaging drug for glioma and is indicated for use with PET to differentiate recurrent or progressive glioma from treatment-related change, in conjunction with other diagnostic evaluations, in adults and pediatric patients 1 month of age and older.

Read more on our website here: https://bit.ly/3TF0T66

SELECTED IMPORTANT SAFETY INFORMATION
● Image misinterpretation may occur with PIXCLARA PET. Equivocal findings may occur with PIXCLARA PET, including low-level or atypical uptake patterns, which may result in false positive or false negative interpretations.
● PIXCLARA involves exposure to small amounts of radioactivity; long-term cumulative radiation exposure is associated with increased cancer risk.
● Adverse reactions that occurred in ≥0.5% of patients receiving PIXCLARA were headache (0.5%).
● Adverse reactions that occurred in

The U.S. FDA has granted Fast Track designation for Telix’s BiPASS® program, evaluating 68Ga-PSMA-PET imaging alongside ...
29/09/2026

The U.S. FDA has granted Fast Track designation for Telix’s BiPASS® program, evaluating 68Ga-PSMA-PET imaging alongside MRI before prostate cancer biopsy.

BiPASS is investigating an imaging-first approach designed to help physicians identify which patients may benefit from biopsy and where it should be targeted.

The designation recognizes the program’s potential to address an important unmet need and supports more frequent engagement with the FDA as Telix advances BiPASS towards a planned new drug application.

Learn more: https://telixpharma.com/news-views/telix-granted-fda-fast-track-designation-for-bipass-pre-biopsy-prostate-cancer-imaging/

⏰ Last chance to double your impact.Today is the last Dollar Match Day for the Prostate Cancer Foundation of Australia’s...
23/09/2026

⏰ Last chance to double your impact.

Today is the last Dollar Match Day for the Prostate Cancer Foundation of Australia’s The Long Run.

Every dollar donated today will again be matched by Telix, helping to fund groundbreaking research and essential support services for Australian men living with prostate cancer.

If you've been thinking about giving, today is the day to make your contribution go twice as far.

👉 Donate now: thelongrun.org.au 💙

Thank you to everyone who joined us in person in New York, and online yesterday for Telix’s 2026 R&D Day.A full recordin...
23/09/2026

Thank you to everyone who joined us in person in New York, and online yesterday for Telix’s 2026 R&D Day.

A full recording is now available on demand at the following link: https://telixrdday.stagepro.io/

Address

55 Flemington Road, North
Melbourne, VIC
3051

Opening Hours

Monday 9am - 5pm
Tuesday 9am - 5pm
Wednesday 9am - 5pm
Thursday 9am - 5pm
Friday 9am - 5pm

Website

Alerts

Be the first to know and let us send you an email when Telix Pharmaceuticals Limited posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category